The Medicines Company $MDCO announced its 90-day interim results from Phase 2 clinical trial, ORION-1, evaluating PCSK9si for the treatment of high cholesterol. The results were positive as the top-line data from 501 subjects at Day 90 showed that when treated with the drug, there was a durable and significant reduction in LDL-C (bad cholesterol). Moreover, no material safety signals were observed.